Bausch + Lomb beats Q3 adjusted EPS estimates; raises FY outlook

Overview

• Global eye health firm's Q3 revenue grew 7% yr/yr

• Adjusted EPS for Q3 beat analyst expectations

• Company raised full-year 2026 revenue and adjusted EBITDA guidance

Outlook

• Company raises 2026 full-year revenue guidance to $5.45 bln–$5.55 bln

• Company now expects 2026 adj EBITDA ex-acquired IPR&D of $1.09 bln–$1.14 bln

• Company forecasts 2026 constant currency revenue growth of 6.1%–8.0%

Result Drivers

• MIEBO GROWTH - Co said 42% revenue growth for MIEBO drove pharmaceuticals segment performance

• CONTACT LENSES - Co said daily SiHy contact lenses drove Vision Care segment growth

• PREMIUM IOL - Co said premium intraocular lenses drove Surgical segment growth

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Bausch + Lomb Corp is $19.45, about 10.4% above its October 27 closing price of $17.62

• The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 18 three months ago

Reuters Recommended Reads

• Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption

• Oct 28 - GE Healthcare Q3 profit beats estimates on advanced imaging segment

• Oct 27 - HCA Healthcare Q3 revenue rises on admissions, emergency room visits growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)